Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01042106 · ClinicalTrials.gov registry record · Phase 1
Safety, Pharmacokinetics and Pharmacodynamics of DSP-8658 in Patients With Type 2 Diabetes Mellitus and Healthy Adults
A Phase 1 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01042106 is a Phase 1 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 40 participants.
The verdict
NCT01042106, a Phase 1 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of DSP-8658 in patients with Type 2 diabetes mellitus and healthy adults.
Interventions
- DRUG Placebo
- DRUG DSP-8658
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2009-11 |
| Est. Completion | 2010-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01042106
The ClinicalTrials.gov registry entry for NCT01042106 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01042106 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01042106 about?
NCT01042106 is a clinical study titled "Safety, Pharmacokinetics and Pharmacodynamics of DSP-8658 in Patients With Type 2 Diabetes Mellitus and Healthy Adults". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of DSP-8658 in patients with Type 2 diabetes mellitus and healthy adults.
What is the current status of trial NCT01042106?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2009-11. Estimated completion is 2010-07.
What interventions are being tested in trial NCT01042106?
The interventions under investigation include: Placebo (DRUG), DSP-8658 (DRUG).
Who is sponsoring clinical trial NCT01042106?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.